Ipamorelin is usually described, including by vendors selling it, as a more "selective" growth hormone secretagogue than older compounds in its class. That claim has some real pharmacological basis, worth understanding on its own terms.
What It Is
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone releasing peptide (GHRP) family, acting on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It's frequently paired with CJC-1295 in combination protocols, on the theory that stimulating growth hormone release through two different receptor pathways simultaneously (ghrelin receptor and GHRH receptor) produces a larger effect than either alone.
Regulatory Status
Ipamorelin is not FDA-approved and is not currently eligible for pharmacy compounding as a stand-alone drug substance. It's sold as a research chemical, not intended for human use under its current labeling.
What the Research Shows
Early research, including some human studies from the 1990s and 2000s, suggested ipamorelin stimulates growth hormone release with comparatively less effect on cortisol and prolactin than older GHRPs, which is the basis for its "selective" reputation. However, this research predates modern trial standards in several cases and hasn't been extended into the kind of large, well-controlled trials that would establish a modern safety and efficacy profile for the doses and combination protocols commonly used today.
Safety Considerations
Because it stimulates growth hormone release, the same theoretical concerns around insulin sensitivity and long-term growth hormone elevation discussed for other secretagogues apply here as well. Formal long-term human safety data, particularly for the extended-use protocols common in non-clinical settings, doesn't exist.
The Bottom Line
Ipamorelin's selectivity claim has a real basis in older pharmacological research, which distinguishes it somewhat from peptides with essentially no human data at all, but "more selective than an older compound" is a meaningfully different claim than "proven safe and effective," and the modern trial evidence to support the latter simply isn't there.
How It's Typically Combined
Ipamorelin is frequently paired with CJC-1295, discussed in this site's dedicated guide, on the theory that combining a ghrelin-receptor secretagogue with a GHRH-receptor analog produces a larger combined growth hormone pulse than either alone. This combination theory has some pharmacological logic behind it, but like the individual compounds, hasn't been established through a dedicated modern controlled trial specifically testing the combination.
Comparing It to Older GHRPs
Ipamorelin is directly compared to GHRP-6 in this site's dedicated comparison guide, which lays out the specific selectivity and appetite-effect differences between them in more depth. That comparison is a useful model for evaluating any two compounds within the same peptide family: understanding the specific pharmacological distinction between them, rather than treating the whole category as interchangeable.